#China #Suzhou #INHBE #RBD3133 #Ribo Life

Ribo Life Science Submits Phase I Clinical Trial Application

In a significant development for the fight against obesity, Suzhou Ribo Life Science, alongside its subsidiary Ribocure Pharmaceuticals AB, has successfully submitted a Clinical Trial Application (CTA) for RBD3133 to conduct a Phase I study in the European Union. This innovative siRNA therapeutic targets INHBE (Inhibin Beta E subunit), marking a promising potential intervention for obesity and related health issues.

Understanding the Implications of Obesity

Obesity has emerged as a global public health crisis, affecting over one billion individuals worldwide. It is closely linked to multiple comorbidities, such as type 2 diabetes, cardiovascular diseases, and other health complications. Despite advancements in treatment modalities, there remains a pressing demand for novel therapies that can effectively address the underlying biological mechanisms driving this metabolic disorder and provide sustainable clinical benefits.

Targeting INHBE

RBD3133 has been specifically designed to selectively inhibit INHBE, a gene encoding the Activin E protein. Genetic studies indicate that individuals carrying loss-of-function variants in the INHBE gene exhibit healthier fat distribution, improved metabolic parameters, and a reduced risk of coronary heart disease and type 2 diabetes. These findings underscore the relevance of INHBE as a promising therapeutic target in addressing obesity and its associated metabolic disorders.

The Phase I Clinical Trial

The Phase I clinical trial will be a randomized, placebo-controlled study aimed at evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of RBD3133 when administered subcutaneously to participants diagnosed with overweight or obesity. This will be the first time RBD3133 will be assessed in humans and will pave the way for further clinical development of this groundbreaking therapy.

Dr. Anders Gabrielsen, Ribo's Chief Medical Officer, stated, "The submission of the CTA represents a significant advancement for our cardiometabolic pipeline, highlighting our capacity to translate compelling human genetic insights into innovative RNAi drugs."

A Milestone in Ribo's siRNA Development Portfolio

RBD3133 marks a crucial milestone in Ribo's siRNA development strategy focused on cardiovascular and metabolic disorders. This drug candidate is expected to play a key role in treating cardiovascular and metabolic complications resulting from obesity. As Ribo's inaugural drug candidate targeting obesity, RBD3133 reflects the company’s strategic commitment to developing innovative treatments for large patient populations facing unmet medical needs.

About Ribo Life Science and Ribocure Pharmaceuticals

Suzhou Ribo Life Science Co., Ltd. (Ribo, 06938.HK) is a prominent biopharmaceutical player dedicated to the development and commercialization of therapeutics based on small interfering RNA (siRNA). With a robust and differentiated product pipeline supported by vertically integrated technology platforms, Ribo focuses on critical disease areas, including cardiovascular and metabolic disorders, as well as liver and kidney diseases. Through ongoing innovation, Ribo aims to provide revolutionary siRNA treatment solutions globally. For more information, visit www.ribolia.com.

As a foreign subsidiary of Suzhou Ribo Life Science, Ribocure Pharmaceuticals AB is committed to the global development of life-saving oligonucleotide therapies, concentrating on drug substance development, pipeline expansion, novel target ideas, and building innovative clinical trial capabilities to address genuine unmet medical needs worldwide. More information can be found at www.ribocure.com.